Recent guideline updates for squamous cell skin cancer add adjuvant cemiplimab as a preferred option for certain patients with very high-risk disease.
Guidelines | Guideline Updates for CSCC: Optimizing Outcomes in High-Risk Patients
Guideline Updates for CSCC: Optimizing Outcomes in High-Risk Patients
Articles
Videos
Systemic therapy for CSCC is evolving toward earlier use, combination and de-escalation strategies, and biomarker-driven personalization to improve outcomes and reduce toxicity.
Multidisciplinary collaboration is essential in managing high-risk CSCC, helping clinicians overcome logistical barriers to deliver coordinated, individualized care.
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
3
ACA Enrollment Erosion Deepens After Open Enrollment Ends
4
Efgartigimod Effective in Broad Subsets of Patients With gMG
5